<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>992</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10640549</PubmedId>
            <Abstract>Linear epitopes on the rabies virus nucleoprotein (N) recognized by six MAbs raised against antigenic sites I (MAbs 6-4, 12-2 and 13-27) and IV (MAbs 6-9, 7-12 and 8-1) were investigated. Based on our previous studies on sites I and IV, 24 consecutively overlapping octapeptides and N- and C-terminal-deleted mutant N proteins were prepared. Results showed that all three site I epitopes studied and two site IV epitopes (for MAbs 8-1 and 6-9) mapped to aa 358-367, and that the other site IV epitope of MAb 7-12 mapped to aa 375-383. Tests using chimeric and truncated proteins showed that MAb 8-1 also requires the N-terminal sequence of the N protein to recognize its binding region more efficiently. Immunofluorescence studies demonstrated that all three site I-specific MAbs and one site IV-specific MAb (7-12) stained the N antigen that was diffusely distributed in the whole cytoplasm; the other two site IV-specific MAbs (6-9 and 8-1) detected only the N antigen in the cytoplasmic inclusion bodies (CIB). An antigenic site II-specific MAb (6-17) also detected CIB-associated N antigen alone. Furthermore, the level of diffuse N antigens decreased after treatment of infected cells with cycloheximide. These results suggest that epitopes at site I are expressed on the immature form of the N protein, but epitope structures of site IV MAbs 6-9 and 8-1 are created and/or exposed only after maturation of the N protein.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>119-27</ArticlePages>
            <ArticleTitle>Mapping of epitopes and structural analysis of antigenic sites in the nucleoprotein of rabies virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Goto</LastName>
                    <ForeName>H</ForeName>
                </Author>
                <Author>
                    <LastName>Minamoto</LastName>
                    <ForeName>N</ForeName>
                </Author>
                <Author>
                    <LastName>Ito</LastName>
                    <ForeName>H</ForeName>
                </Author>
                <Author>
                    <LastName>Ito</LastName>
                    <ForeName>N</ForeName>
                </Author>
                <Author>
                    <LastName>Sugiyama</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Kinjo</LastName>
                    <ForeName>T</ForeName>
                </Author>
                <Author>
                    <LastName>Kawai</LastName>
                    <ForeName>A</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Veterinary Public Health, Faculty of Agriculture, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antigens, Viral;Nucleocapsid Proteins;Nucleoproteins;Peptides;Recombinant Fusion Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Antibodies, Monoclonal(immunology; metabolism); Antigens, Viral(genetics; immunology; metabolism); Blotting, Western; Cell Line; Enzyme-Linked Immunosorbent Assay; Epitope Mapping; Fluorescent Antibody Technique, Indirect; Molecular Sequence Data; Nucleocapsid Proteins(chemistry; genetics; immunology; metabolism); Nucleoproteins(chemistry; genetics; immunology; metabolism); Peptides(chemical synthesis; immunology); Plasmids(genetics); Rabies virus(genetics; immunology; physiology); Recombinant Fusion Proteins(immunology; metabolism); Sequence Deletion</ArticleMeshHeadingsList>
            <Journal>
                <Volume>81</Volume>
                <Issue>Pt 1</Issue>
                <Title>The Journal of general virology</Title>
                <Issn>1465-2099</Issn>
                <MedlineTa>J Gen Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP 358-367</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RFFRDEKELQ</LinearSequence>
                        <StartingPosition>358</StartingPosition>
                        <EndingPosition>367</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAZ07886.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000471</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>53702</EpitopeId>
                <ReferenceStartingPosition>358</ReferenceStartingPosition>
                <ReferenceEndingPosition>367</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope was deduced from epitope mapping studies of overlapping 8 mers using a panel of mAbs raised against antigenic sites I and IV.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>12336</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAbs were described in a previous publication.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>mAbs 6-4, 12-2, and 13-27 were directed against the antigenic site I and mAbs 6-9, 7-12, and 8-1 were directed against the antigenic site IV.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 6-4, mAb 8-1, mAb13-27, mAb 12-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>NP 358-367</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RFFRDEKELQ</LinearSequence>
                                        <StartingPosition>358</StartingPosition>
                                        <EndingPosition>367</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAZ07886.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000471</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>16164</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAbs were described in a previous publication.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>549</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunohistochemistry of rabies (RB-HL strain)-infected BHK-21 cells was performed.  Antigenic site 1-directed mAbs 6-4, 12-2, and 13-27 all gave staining patterns of diffuse N-protein in rabies infected cells.  One antigenic site IV mAb, 7-12, also gave a similar diffuse staining pattern.  In one of the experimental groups, cycloheximide was added to the culture medium at 48 hours post-infection for 1 hour to stop N-protein translation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 6-4,  mAb 13-27, mAb 12-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Rabies virus</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000471</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>16166</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAbs were described in a previous publication.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>549</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunohistochemistry of rabies (RB-HL strain)-infected BHK-21 cells was performed. Site-IV directed mAbs 8-1 and 6-9 both stained cytoplasmic inclusion bodies.  In one of the experimental groups, cycloheximide was added to the culture medium at 48 hours post-infection for 1 hour to stop N-protein translation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 8-1, mAb 6-9</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Rabies virus</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000471</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>16167</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was described in a previous publication.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The reactivity of mAb 8-1 toward wild-type and chimeric N-proteins from Hep-Flury and RC-HL strains of rabies virus was demonstrated.  The mAb 8-1 reactivity profile indicates that N-terminal amino acids (1-42) of RC-HL strain N-protein are required for efficient binding to epitope. Conversely, mAb 12-2 which was directed against I was equally reactive toward N-protein from both strains.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 8-1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>nucleoprotein</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>AAZ07886.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10000471</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>16168</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was described in a previous publication.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The reactivity of mAb 12-2 toward wild-type and chimeric N-proteins from Hep-Flury and RC-HL strains of rabies virus was demonstrated.  mAb 12-2, directed against antigenic site I, was equally reactive toward wild-type and chimeric N-protein from both strains of rabies.  Conversely, the reactivity of mAb 8-1 (directed against antigenic site IV) indicates that it requires the N-terminus of the RC-HL strain for efficient binding.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 12-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>nucleoprotein</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>AAZ07886.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10000471</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP 375-383</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TKTDVALA</LinearSequence>
                        <StartingPosition>375</StartingPosition>
                        <EndingPosition>382</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAZ07886.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000471</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>64682</EpitopeId>
                <ReferenceStartingPosition>375</ReferenceStartingPosition>
                <ReferenceEndingPosition>383</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This epitope was deduced from western blot analysis of C-terminal truncations of N-protein.  Authors provide data that this epitope forms one of two non-overlapping and distinct Antigenic Site IV epitopes.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>16165</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was described in a previous publication.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>38</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>mAb 7-12 was directed against the antigenic site IV of rabies virus.  A staining pattern of diffusely distributed N-protein was also obtained with antigenic site I mAbs, 12-2,  13-27, and 6-4.  In one of the experimental groups, cycloheximide was added to the culture medium at 48 hours post-infection for 1 hour  to stop N-protein translation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 7-12</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Rabies virus</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000471</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>12337</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was described in a previous publication.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>mAb 7-12 was directed against the antigenic site IV of rabies virus.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 7-12</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>N-protein (N-terminal truncation residues 1-383)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MDADKIVFKVNNQVVSLKPEIIVDQYEYKYPAIKDLKKPCITLGKAPDLNKAYKSVLSGMNAAKLDPDDVCSYLAAAMQFFEGTCPEDWTSYGILIARKGDKITPDSLVEIKRTDVEGNWALTGGMELTRDPTVSEHASLVGLLLSLYRLSKISGQNTGNYKTNIADRIEQIFETAPFVKIVEHHTLMTTHKMCANWSTIPNFRFLAGTYDMFFSRIEHLYSAIRVGTVVTAYEDCSGLVSFTGFIKQINLTAREAILYFFHKNFEEEIRRMFEPGQETAVPHSYFIYFRSLGLSGKSPYSSNAVGHVFNLIHFVGCYMGQVRSLNATVIAACAPHEMSVLGGYLGEEFFGKGTFERRFFRDEKELQEYEAAELTKTDVALAD</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>383</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAZ07886.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000471</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

